HK Stock Market Move | SIMCERE PHARMA (02096) rose more than 3%, and the approval was granted for the domestic listing of Dalirelai tablets for the treatment of insomnia.

SIMCERE PHARMA (02096) rose more than 3%, and as of the time of writing, it was up 2.17% to 10.34 Hong Kong dollars, with a trading volume of 187 million Hong Kong dollars. In terms of news, according to Medicine Magic Cube, on June 20, the NMPA official website showed that SIMCERE PHARMA's daridorexant hydrochloride tablets have been approved for listing in China for the treatment of insomnia. Daridorexant is a potential Best-in-Class innovative drug developed by Idorsia (originally from Actelion) targeting orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R). Unlike traditional sedative-hypnotic drugs that promote sleep by sedating the brain, daridorexant helps insomnia patients fall asleep and stay asleep by blocking the binding of orexin neuropeptides (orexin 1 and orexin 2) with their receptors, without the feeling of hangover or drowsiness the next day. In January 2022, daridorexant hydrochloride tablets were approved for listing in the United States under the brand name Quviviq for the treatment of adult insomnia patients with difficulty falling asleep and/or staying asleep. In November of the same year, SIMCERE PHARMA reached an agreement with Idorsia to obtain the development and commercialization rights of daridorexant in the Greater China region for a total transaction amount of 50 million US dollars. Previously, daridorexant hydrochloride tablets had been approved for listing in the United States, United Kingdom, European Union, Switzerland, and Canada.